 Logo used since 1961 | |
 Global headquarters inNihonbashi | |
Native name | 武田薬品工業株式会社 |
|---|---|
Romanized name | Takeda Yakuhin Kōgyō kabushiki gaisha |
| Formerly | Chobei Takeda & Co., Ltd. (1925–1943) Takeda Pharmaceutical Industries, Ltd. (English name only 1943–1961) Takeda Chemical Industries, Ltd. (English name only 1961–2004)[2] |
| Company type | PublicKK |
| Industry | Pharmaceuticals |
| Founded | 12 June 1781; 244 years ago (1781-06-12) (as Omiya) 29 January 1925; 100 years ago (1925-01-29) (company) |
| Founder | Chobei Takeda I |
| Headquarters | , Japan |
Key people | Yasuchika Hasegawa (Chairman of the Board) Christophe Weber[3] (President &CEO) |
| Revenue |  ¥4.03 trillion (FY 2022)[* 1] |
| ¥490.51 billion (FY 2022)[* 1] | |
| ¥317.02 billion (FY 2022)[* 1] | |
| Total assets | ¥13.96 trillion (FY 2022)[* 1] |
| Total equity | ¥6.35 trillion (FY 2022)[* 1] |
| Owners |
|
Number of employees | |
| Website | www |
| Footnotes / references | |
TheTakeda Pharmaceutical Company Limited[1] (武田薬品工業株式会社,Takeda Yakuhin Kōgyō kabushiki gaisha)[takeꜜdajakɯçiŋkoꜜːɡʲoː] is a Japanesemultinationalpharmaceutical company. It is the third largest pharmaceutical company inAsia, behindSinopharm andShanghai Pharmaceuticals, and one of the top 20largest pharmaceutical companies in the world by revenue (top 10 following its merger withShire). The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year.[7] The company is focused ononcology, rare diseases,neuroscience,gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located inChuo-ku,Osaka, and it has an office inNihonbashi,Chuo,Tokyo.[8][9] In January 2012,Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.[10] As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.[11]
 | This sectionmay be in need of reorganization to comply with Wikipedia'slayout guidelines. Please help byediting the article to make improvements to the overall structure.(October 2021) (Learn how and when to remove this message) |
Takeda Pharmaceuticals was founded in 1781 byChobei Takeda, and was incorporated on January 29, 1925.[12]
One of the firm's mainstay drugs is Actos (pioglitazone), a compound in thethiazolidinedione class of drugs used in the treatment oftype 2 diabetes. It was launched in 1999.[13]
In February 2005, Takeda acquiredSan Diego,California, based Syrrx, a company specializing in high-throughputX-ray crystallography, for US$270 million.[14]
In February 2008, Takeda acquired the Japanese operations ofAmgen and rights to a dozen of the California biotechnology company's pipeline candidates for the Japanese market.[15] In April, Takeda acquiredMillennium Pharmaceuticals ofCambridge,Massachusetts, a company specializing incancer drug research, for US$8.8 billion.[16] The acquisition brought inVelcade, a drug indicated for hematological malignancies, as well as a portfolio of pipeline candidates in the oncology, inflammation, and cardiovascular therapeutic areas. Millennium now operates as an independent subsidiary.[16] In May, the companylicensed non-exclusively theRNAi technology platform developed byAlnylam Pharmaceuticals, creating a potentially long-term partnership between the companies.[17]
In September 2011, Takeda acquiredNycomed for€9.6 billion.[18]
In May 2012, Takeda purchased Brazilian pharmaceutical company Multilab forR$540 million.[19] In June, Takeda announced it would acquire URL Pharma, then run by the founder's sonRichard Roberts, for US$800 million.[20]
In September 2014, Takeda announced it would team up withBioMotiv to identify and develop new compounds over a five-year period, worth approximately US$25 million.[21] On 30 September 2014, Takeda announced it would expand a collaboration with MacroGenics, valued up to US$1.6 billion. The collaboration focused on the co-development of the preclinicalautoimmune compound MGD010. MGD010 is a therapy which targets theB-cell surface proteinsCD32B andCD79B, and is indicated forlupus andrheumatoid arthritis.[22]
In 2015, Takeda sold its respiratory drugs business toAstraZeneca for $575 million (about £383 million), which includedroflumilast andciclesonide.[23] On November, the U.S.Food and Drug Administration approvedIxazomib developed by Takeda for use in combination withlenalidomide anddexamethasone for the treatment ofmultiple myeloma after at least one prior therapy.[24]
In December 2016, the company spun out its neuroscience research division into Cerevance, a joint venture along with Lightstone Ventures.[25]
In February 2017, Takeda acquiredAriad Pharmaceuticals for $5.2 billion, expanding the company's oncology and hematology divisions.[26]
In January 2018, the company acquired stem cell therapy developerTiGenix for up to €520 million ($632 million).[27]
In January 2019, Takeda acquiredShire for more thanUS$50 billion.[28][29] In October, Takeda announced it had sold a portfolio of over-the-counter and prescription medicines in theMiddle East andAfrica to Swiss pharmaceuticals company Acino International for more than $200 million.[30][31]
In January 2020, Takeda announced a research partnership with theMassachusetts Institute of Technology (MIT) to advance discoveries inartificial intelligence and health. The MIT-Takeda Program is housed in theMIT Jameel Clinic, and is led by ProfessorJames J. Collins, with a steering committee led by ProfessorAnantha P. Chandrakasan, dean of theMIT School of Engineering, and Anne Heatherington, senior vice president and head of Data Sciences Institute (DSI) at Takeda.[32][33][34] In March 2020, Takeda announced that it has entered into an exclusive agreement to divest a portfolio of non-core products inLatin America to Hypera S.A. for a total value of $825 million.[35]
In March 2021, the company announced it would acquire Maverick Therapeutics, Inc. and its two major programsTAK-186 (MVC-101) in trials for the treatment ofEGFR-expressing tumours andTAK-280 (MVC-280) for use in the treatment of patients with B7H3-expressing tumors.[36] In October, they acquiredGammaDelta Therapeutics and its gamma delta (γδ)T cell immunotherapy programme.[37][38]
In January 2022, Takeda announced it would exercise its option to acquireAdaptate Biotherapeutics and its antibody-based γδ T cell technology, reuniting Adaptate and its former parent company, GammaDelta Therapeutics, in a single organisation.[39][40] In December of the same year, the company announced it would acquire Nimbus Lakshmi, Inc. and its lead compoundNDI-034858 which is anallostericTYK2 inhibitor for the treatment of various autoimmune diseases,[41] from Nimbus Therapeutics, LLC for up to $6 billion.[42][43]
In February 2024, Takeda Pharmaceutical gained approval from the FDA forEohilia, the first oral approval for allergic inflammation of theesophagus for patients 11 years and older. At the time of the announcement, the treatmentDupixent fromSanofi andRegeneron was the only alternative.[44]
In May 2024, Takeda announced it would be laying off 641 employees based inMassachusetts between July 2024 and March 2025 as part of a restructuring. It was expected to affect 495 people based inCambridge and 146 people inLexington.[45]
In October 2025, Takeda signed an $11.4 billion deal with China'sInnovent Biologics to help the company accelerate the development of immuno-oncology and antibody-drug conjugate cancer therapies. The deal includes a $1.2 billion upfront payment from Takeda.[46]
In 1977, Takeda first entered the U.S. pharmaceutical market by developing a joint venture withAbbott Laboratories called TAP Pharmaceuticals.[47] Through TAP Pharmaceuticals Takeda and Abbott launchedblockbuster drugs Lupron (leuprorelin), in 1985,[48] then Prevacid (lansoprazole), in 1995.[49]
In 2001, TAP's illegal marketing of Lupron resulted in both civil and criminal charges by the U.S. Department of Justice and the Illinois attorney general for federal and statemedicare fraud. TAP was fined $875 million, then reported as thelargest pharmaceutical settlement in history.[50][51]
In March 2008, Takeda andAbbott Laboratories announced plans to conclude their 30-year-old joint venture, TAP Pharmaceuticals.[52] The split resulted in Abbott acquiring U.S. rights to Lupron and the drug's support staff.[53] Takeda received rights to Prevacid and TAP's pipeline candidates.[53] The move also increased Takeda's headcount by 3,000 employees.[54]
In May 2019, Takeda sold itsXiidra dry-eye drug business toNovartis for $5.3 billion, $3.4 billion upfront and up-to $1.9 billion in sales milestones.[55][56]
In November 2019, Takeda entered an agreement to sell its over-the-counter and prescription drugs businesses in Russia, Georgia, Armenia, Azerbaijan, Belarus, Kazakhstan, and Uzbekistan toStada Arzneimittel for $660 million.[57]
In April 2020, the company divested rights to 110 over-the-counter and prescription medicines for DKK 4.6 billion (670 million USD) toOrifarm.[58][59][60][61][62] Through this acquisition, Orifarm also gained control of two production facilities in Łyszkowice, Poland, and Hobro, Denmark.[63]
In June 2020, Takeda announced that it was divesting 18 over-the-counter and prescription drugs marketed in the Asia-Pacific region to South Korea'sCelltrion in a deal worth $278 million.[56][64][65][66]
Also in 2020, Takeda soldTachoSil to Corza Health, Inc. for €350 million.[67]
In April 2015 Takeda agreed to pay a settlement of $2.37 billion to an estimated 9,000 people who submitted claims alleging thatpioglitazone was responsible for giving them bladder cancer. The company said the decision is expected to resolve the “vast majority” of these cases. Takeda will put the money into a settlement fund if 95 percent of plaintiffs agree to the accord, according to which each claimant would get an average $267,000. However, the exact amount for each plaintiff will be evaluated based on cumulative dosage, extent of injuries and history of smoking.[68] In 2014, a plaintiff was awarded $9 billion in punitive damages after a federal court found Takeda hid the cancer risks of their diabetes medicine,[69] but the amount was later reduced to $26 million by a judge who deemed the charge excessive.[70]
Takeda is a corporate partner ofHuman Rights Campaign, a largeLGBT advocacy organization.[71]
And it didn't include earlier-announced deals completed in 2019, such as Takeda Pharmaceutical's £46 billion ($58.6 billion) purchase of Shire.
Media related toTakeda Pharmaceutical Company at Wikimedia Commons| International | |
|---|---|
| National | |
| Academics | |
